IP Federation warns against ‘blanket ban’ on in-house counsel at UPC

UK trade association weighs in on Microsoft UPC appeal which deals with issue of representation | Former CIPA head says court should not “divide” European patent profession | SMEs could be forced to opt out patents due to counsel costs.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Unified Patent Court

WATCH: Navigating parallel EPO and UPC revocation actions: strategies, opportunities, and risks

23 May 2026 Managing parallel revocation actions requires a meticulous approach to forum choice and sequencing. This presentation unpacks the lessons learned from the first year of simultaneous EPO and UPC proceedings, offering tactics to leverage opportunities and minimise cross-border risks.

Unified Patent Court

WATCH: Facilitating access to the UPC—economics and navigating the UPC-US patent nexus

15 May 2026 Understanding the economic mechanisms and cross-border interactions of the UPC is crucial for modern patent litigation. This session untangles the complexities of evidence gathering and cost security, highlighting the critical interplay between European proceedings and US patent strategies.

Unified Patent Court

WATCH: Latest developments from the UPC

14 May 2026 Are life sciences cases gaining momentum in the new Unified Patent Court? This session provides a critical update on the UPC's evolving jurisprudence, looking at emerging legal tests and the specific challenges of preliminary injunctions for life sciences products.

More features

China’s medtech shake-up forces rethink on pricing, IP and innovation

LSD trade secrets suit over clinical trail info thrown out by judge

HGF expands European offering with pair of in-house hires

What’s at stake in Australia’s biggest pharma patent appeal in years?

Vinson & Elkins grows West Coast patent and trade secrets bench

Will Mounjaro and Zepbound get their first US generic rival?

King & Spalding continues hiring spree from pre-merged Winston

Ashurst Perkins Coie opens its doors following landmark merger

IP Federation warns against ‘blanket ban’ on in-house counsel at UPC

More on this story

Editor's picks

Editor's picks

More features